Literature DB >> 11007833

Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept.

P Leitienne1, D Fouque, D Rigal, P Adeleine, M C Trzeciak, M Laville.   

Abstract

BACKGROUND: At the concentrations used in haemodialysis and in a dose-dependent way, unfractionated heparin (UFH) and, to a lesser degree, a low-molecular-weight heparin (LMWH) stimulate polymorphonuclear cells (PMN) in vitro, and could act in synergy with the stimulatory effect of dialysis membranes in vivo. To examine this hypothesis, we studied the effects of different heparin types and regimens on blood PMNs during haemodialysis sessions.
METHODS: Ten haemodialysed patients were studied during regular dialysis sessions on a cellulose triacetate membrane (CT 110 G; 1.10 m(2); Baxter), with four different random heparin protocols: one high-UFH regimen (HHR) at 90 IU/kg body-weight (b.w.) and one low-UFH regimen (LHR) at 50 IU/kg b.w., and with a LMWH (nadroparin calcium) at 85 (HHR) or 45 (LHR) IU/kg b.w. Blood granulocytes, platelet counts, and plasma granulocyte degranulation products (elastase, lactoferrin) were measured serially during 4 h dialysis sessions.
RESULTS: After 10 min, the reduction in PMNs with UFH was 29.5% for HHR (P<0.01) and 28.5% for LHR (P<0.01), and only 16.8 and 18.6% with LMWH (NS), significantly higher for HHR with UFH than with LMWH (P<0.01). At 60 min, the elastase increase with HHR was greater, 61% with UFH (P<0.01) and 37.8% with LMWH (P<0.01), significantly higher than LHR for UFH (P<0.05) or LMWH (P<0.05). The overall decrease in platelets (with LMWH P<0.01) and the overall increase in lactoferrin (P<0.001) were not different between heparinization procedures.
CONCLUSION: Under a conventional heparin regimen, the PMN variation during the course of the dialysis session suggests a more biocompatible effect of LMWH over UFH. In addition, the variation of elastase favours the lower dose, whatever the type of heparin. Heparin type and dose should therefore be considered in studies addressing biocompatibility in haemodialysis: a low dose of LMWH may be viewed as a better biocompatible treatment with regard to leukocyte stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007833     DOI: 10.1093/ndt/15.10.1631

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  The effects of citrate dialysate in hemodialysis on polymorphonuclear elastase interaction with tissue factor and its inhibitor.

Authors:  Jiameng Li; Si Sun; Mei Han; Liya Wang; Ruoxi Liao; Yuqin Xiong; Yupei Li; Heng Jiang; Zheng Qin; Anil Maharjan; Mario Cozzolino; Alexander Zarbock; Baihai Su
Journal:  Ann Transl Med       Date:  2019-08

Review 2.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

Review 3.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

4.  Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients.

Authors:  Louise Schilder; S Azam Nurmohamed; Pieter M ter Wee; Nanne J Paauw; Armand R J Girbes; Albertus Beishuizen; Robert H J Beelen; A B Johan Groeneveld
Journal:  BMC Nephrol       Date:  2014-01-17       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.